1. Studer H, Gerber H, Peter HJ. Multinodular goiter. In: Endocrinology. Ed. DeGroot LJ, W.B. Saunders Cie., Philadelphia, vol.1, chapt. 46, p 722-23, 1989.
2. Studer H, Ramelli F. Simple goiter and its variants: Euthyroid and hyperthyroid multinodular goiters.Endocr Rev 3: 40, 1982.
10. Holtzapfel H-P, Bergner B, Wonerof P, Paschke R. Expression of Gas proteins and TSH receptor signaling in hyperfunctioning thyroid nodules with TSH receptor mutations. European J Endocrinology 147: 109-116,2002
10a.Parma J, Duprez L, Van Sande J,et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenoma. J Clin Endocrinol Metab 82:2695-2701,1997
10b. Takeshita A, Nagayama Y, Yokoyama N, et al. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin. Endocrinol Metab 80:2607-2611,1995
10c. Lax SF, Semlitsch G, Schauer S, et al. Point mutations of the thyrotropin receptor gene in autonomously functioning thyroid gland nodules: correlation with clinical findings and morphology.Vern Dtsch Ges Pathol 81:145-150,1997
10ca. Pinducciu C, et al.Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. Eur J Endocrinol 138: 37-40, 1998.
10ca1. Nogueira CR, Kopp P, Arseven OK, Santos CL, Jameson JL, Madeiros-Neto G. Thyrotropin receptor mutations in hyperfunctioning adenomas from Brazil. Thyroid 9 :1063-1068,1999.
10cb. Derwahl M, et al. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab 81:1898-1904,1996.
10cb1. Pesani L, Lania A, Alberti L, Romoli R, Mantovani G, Filetti S, Spada A, Conti M. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J Clin Endocrinol Metab 85:2872-2878, 2000
10d. Van Sande J, Massart C, Costagliola S, et al. Specific activation of the thyrotropin receptor by trypsin. Mol Cell Endocrinol 119:161-168,1996
10e. Parma J, Van Sande J, Swillens S, et al. Somatic mutations causing constitutive activation of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Mol Endocrinol 9:725-733,1995
10ea. Deleu S, Allory Y, Radulescu A, Pirson I, Carrasco N, Corvilain B, Salmon I, France B, Dumont JE, Van Sande J, Maenhaut C. Characterization of autonomous thyroid adenome:metabolism,gene expression, and pathology. Thyroid 10:131-140,2000
10eb. Fuhrer D, Lewis MD, Alkhafaji F, Starkey K, Paschke R, Wynford-Thomas D, Eggo M, Ludgate M.Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context. Endocrinology. 144: 4018-30, 2003
10ec. Al-Khafaji F, Wiltshire M, Fuhrer D, Mazziotti G, Lewis MD, Smith PJ, Ludgate M.Biological activity of activating thyrotrophin receptor mutants: modulation by iodide.J Mol Endocrinol. 2005 Feb;34(1):209-20.
10f. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenoma- -a note of caution(editorial). J Clin Endocrinol Metab 81:1783-2785,1996
10fa. Krohn K, Paschke R. Somatic mutations in nodular disease. Mol Genet Metab 75:202-208, 2002
10fb. Derwahl M and Studer H. Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes;109:250-60, 2001.
10fc. Trulzsch B, Krohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F, Fuhrer D, Paschke R. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 78:684-91,2001.
13. Hamburger JI. Evolution of toxicity in solitary non-toxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 50:1089,1980.
14. Thomas CG, Croom RD. Current management of the patient with autonomously functioning nodular goiter. Surg Clin North Am 67:315,1987.
15. Bransom CJ, Talbot CH, Henry L, Elemenoglou J. Solitary toxic adenoma of the thyroid gland. Br J Surg 66:590,1979.
16. Horst W, Rösler H, Schneider C, Labhart A. 306 Cases of toxic adenoma: clinical aspects, findings in radioiodine diagnostics, radiochromatography and histology; results of I131 and surgical treatment. J Nucl Med 8:515,1967.
16a. Berglund J, Ericsson UB, Hallengren B. Increased incidence of thyrotoxicosis in Malmo during the years 1988-1990 as compared to the years 1970-1974. J Intern Med. 239:57-62,1996
17. Emrich D, Erlenmaier U, Pohl M, Luig H. Determination of the autonomously functioning volume of the thyroid. Eur J Nucl Med 20:410,1993.
18. McKenzie JM, Zakarija M. Hyperthyroidism. In: Endocrinology. Ed. DeGroot LJ, W.B. Saunders Cie. Philadelphia. vol.1, chapter 43, p. 646-682, 1989.
19. Barth JD, Bakker WH, Hennemann G. Discrepancies between iodine and technetium thyroid scintigraphy. JAMA 240:463, 1978.
20. Sandler MP, Fellmeth B, Salhany KE, Patton JA. Thyroid carcinoma masquerading as a solitary benign hyperfunctioning nodule. Clin Nucl Med 13: 410, 1988.
21. Becker FO, Economou PG, Schwartz TB. The occurrence of carcinoma in "hot" thyroid nodules: report of two cases. Ann Intern Med 58:877,1963.
22. Fujimoto Y, Oka A, Nagataki S. Occurrence of papillary carcinoma in hyperfuntioning thyroid nodule: report of a case. Endocrinol Jpn 19:371,1972.
23. Smyth M, McHenry C, Jarosz H, Lawrence AM, Paloyan E. Carcinoma of the thyroid in patients with autonomous nodules. Am J Surg 54: 448, 1988.
24. Hamburger JI. Solitary autonomously funtioning thyroid lesions: diagnosis, clinical features and pathogenetic considerations. Am J Med 58:740,1975.
25. Eyre-Brooke IA, Talbot CH. The treatment of autonomous functioning thyroid nodules. Br J Surg 69:577,1982.
26. Ratcliffe GE, Cooke S, Fogelman I, Maisey MN. Radioiodine treatment of solitary functioning thyroid nodules. Br J Rad 59:385,1986.
27. Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic nodules with relatively low-dose I131 with low prevalence of hypothyroidism. Ann Int Med 101:488,1984.
28. Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with I131. New Eng J Med 309:1473,1983.
29. Mariotti S, Martino E, Francesconi M, Seccarelli C, Grasso L, Lippi F, Baschieri L, Pinchera A. Serum thyroid auto-antibodies as a risk factor for development of hypothyroidism after radioactive iodine therapy for single thyroid "hot" nodule. Acta Endocrinol (Copenh.) 113:500,1986.
30.Lippi F, Ferrari C, Manetti L, et al. Treatment of solitary autonomous thyroidles by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study Group. J Clin Endocrinol Metab 81:3261-3264,1996
31. Monzani F, Carracio N, Goletti O, et al. Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules : a study of 117 patients. Clin Endocrinol 46: 9-15,1997.
31a. Zingrillo M, Torlantano M, Ghiggi MR, Frusciante A, Varraso A, Liuzzi A, Trischitta V. radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study. Thyroid 10:985-990,200
31a1. Del Prete S, Russo D, Caraglia M, Giuberti G, Marra M, Vitale G, Lupoli G, Abbruzzese A, Capasso E..Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up. Clin Radiol. 56:895-901,2001
31b. Monzani F, Caraccio N, Basolo F, Iacconi P, LiVolsi V, Miccoli P. Surgical and pathological changes after percutaneous ethanol injection of thyroid nodules. Thyroid 10:1087-1092,2000
31b1. Janowitz P, Ackmann S. Long-term results of ultrasound-guided ethanol injections in patients with autonomous thyroid nodules and hyperthyroidism Med Klin. 96:451-6,2001.
31b2. Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, Pacella S, Toscano V, Papini E.Thyroid tissue: US-guided percutaneous laser thermal ablation.Radiology. 2004 Jul;232(1):272-80.
31b3. Dossing H, Bennedbaek FN, Hegedus L.Ultrasound-guided interstitial laser photocoagulation of an autonomous thyroid nodule: the introduction of a novel alternative. Thyroid. 2003 Sep;13(9):885-8.
32. Jackson IMD. Hyperthyroiditis, a diagnostic pitfall. New Engl J Med 293:661,1975.
33. Nicolai TF, Brusso J, Kettrick MA, Roberts R, Beltaos E. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Int Med 140:478,1980.
34. Wolff PD, Daly R. Thyrotoxicosis with painless thyroiditis. Am J Med 60:73,1977.
35. Wolff PD. Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? Endocrine Rev 1:411,1980.
36. Gegick CG, Harring WB. Painless subacute thyroiditis: a report of two cases. N C Med J 38:387,1977.
36a. Iitaka M, Morgenthaler NG, Momotani N, Nagata A, Ishikawa N, Ito K, Katayama S, Ito K.Stimulation of thyroid-stimulating hormone (TSH) receptor antibody production following painless thyroiditis.Clin Endocrinol (Oxf). 2004 Jan;60(1):49-53.
37. Hamburger JI. Occult subacute thyroiditis-diagnostic challenge. Mich Med 70:1125,1971.
38. Morrison J, Caplan RH. Typical and atypical ("silent") subacute thyroiditis in a wife and husband.Arch Int Med 138:45,1978.
39. Gorman CA, Duick DS, Woolner LB, Wahner HW. Transient hyperthyroidism in patients with lymphocytic thyroiditis. Mayo Clinic Proc 53:359,1978.
40. Tokuda Y, Kasagi K, Lida Y, Yamamoto K, Hatabu K, Hidaka A, Konishi J, Ishii Y. Sonography of subacute thyroiditis: changes in the findings during the course of the disease. J Clin Ultrasound 18:21,1990.
41. Vitug AC, Goldman JM. Thyrotoxic silent thyroiditis: a geographic puzzle. Arch Intern Med 145:2263,1985.
42. Schneeberg NG. Silent thyroiditis. Arch Intern Med 143:2214,1983.
43. Parker M, Klein I, Fishman LM, Levey GS. Silent thyrotoxic thyroiditis in association with chronic adrenocortical insufficiency. Arch Intern Med 140:1108,1978.
44. Hamburger JI. Are silent thyroiditis and postpartum silent thyroiditis forms of chronic thyroiditis, or different (new) forms of viral thyroiditis? In: Controversies in clinical thyroidology. Eds. Hamburger JI, Miller JM, Springer-Verlag, New York, 1981, p 21.
45. Farid NR, Hawe BS, Walfish PG. Increased frequency of HLA-DR 3 and 5 in the syndromes of painless thyroiditis with transient thyrotoxicosis: evidence for an autoimmune etiology. Clin Endocrinol 19:699,1983.
46. Dorfman SG, Cooperman MT, Nelson RL, Depuis H, Peake RL, Young RA. Painless thyroiditis and transient hyperthyroidism without goiter. Ann Intern Med 86:24,1977.
47. Vagenakis AG, Braverman LE, Asisi F, Protinai GI, Ingbar SH. Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. New Eng J Med 293:681,1975.
47a. Miyakawa M, Tsushima T, Onoda N, Etoh M, Isozaki O, Arai M, Shizume K, Demura H. Thyroid ultrasonography related to clinical and laboratory findings in patients with silent thyroiditis. J Endocrinol Invest 15:289-95,1992
48. Nicolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ jr. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 142:2281,1982.
49. Nicolai TF, Coombs GJ, McKenzie AK. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism and subacute thyroiditis. Long-term follow-up. Arch Intern Med 141:1455,1981.
49a. Bogazzi F, Bartalena L.Brogioni S, et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow Doppler sonography. Eur J Endocrinol 140:452-456,1999
50. Mariotti S, Martino E, Cuppini C, Lari R, Giani C, Baschieri L, Pinchera A. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. New Engl J Med 307:410,1982.
51. Kinney JS, Hurwitz ES, Fishbein DB et al. Community outbreak of thyrotoxicosis: epidemiology, immunogenetic characteristics, and long-term outcome. Am J Med 84:10,1988.
52. Hedberg CW, Fishbein DB, Janssen RS et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beaf. New Eng J Med 316:993,1987.
53. Faber J,Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment. Eur J Endocrinol 130:350-356,1994
54. Biondi B, Fazio S, Carella C, etal. Cardiac effects of longterm thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334-338,1993
55. Franklyn J, Betteridge J, Holder R, et al. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 41:425-432,1994
56. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82:2592-2595,1997
57. Glinoer D, Lemone M. Goiter and pregnancy. A new insight into an old problem. Thyroid 2:65,1992.
57a. Rodien P, Brèmont C, Raffin Sanson ML, Parma J, Van Sande J, Costagliola S et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. New England Journal of Medicine 339:1823-1826,1998
58. Nisula BC, Ketelslegers J-M. Thyroid-stimulating activity and chorionic gonadotropin. J Clin Invest 54:494,1974.
59. Kenimer JG, Hershman JM, Higgins HP. The thyrotropin in hydatidiform moles is human chorionic gonadotropin J Clin Endocrinol Metab 40:482,1975.
60. Nisula BC, Taliadouros GS. Thyroid function in gestational trophoblastic neoplasia: evidence that the thyrotropic activity of chorionic gonadotropin mediates the thyrotoxicosis of choriocarcinoma. Am J Obstet Gyn 138:77,1980.
61. Amir SM, Endo K, Osathanondh R, Inbar SH. Divergent responses by human and mouse thyroids to human chorionic gonadotropin in vitro. Mol Cell Endocrinol 39:31,1985.
62. Carayon P, Lefort G, Nisula BC. Interaction of human chorionic gonadotropin and human luteinizing hormone with human thyroid membranes. Endocrinol 106:1907,1980.
63. Yoshimura M, Hershman JM, Pang X-P, Berg L, Pekary E. Activation of the thyrotropin (TSH) receptor by human chorionic gonadotropin and luteinizing hormone in Chinese hamster ovary cells expressing functional human TSH receptors. J Clin Endocrinol Metab 77:1009,1993.
64. Carayon P, Amir S, Nisula B, Lissitzky S. Effect of carboxypeptidase digestion of the human choriogonadotropin molecule on its thyrotropic activity. Endocrinol 108:1891, 1981.
65. Cole LA, Kardana A. Discordant results in human chorionic gonadotropin assays. Clin Chem 38:263,1992.
66. Davies TF, Taliaduros GS, Catt KJ, Nisula BC. Assessment of urinary thyrotropin-competing activity in choriocarcinoma and thyroid disease: further evidence for human chorionic gonadotropin interacting at the thyroid cell membrane. J Clin Endocrinol Metab 49:353,1979.
67. Ouchimoura H, Nagataki S, Ito K, Amir SM, Ingbar SH. Inhibition of the thyroid adenylate cyclase response to thyroid-stimulating immunoglobulin G and asialo-human chorionic gonadotropin. J Clin Endocrinol Metab 55: 347,1982.
68. Hoermann R, Broecker M, Grossmann M, Mann K, Derwahl M. Interaction of human chorionic gonadotropin (hCG) and asialo-hCG with recombinant human thyrotropin receptor. J Clin Endocrinol Metab 78:933,1994.
69. Hoermann R, Amir SM, Ingbar SH. Evidence that partially desialylated variants of human chorionic gonadotropin (hCG) are the factors in crude hCG that inhibit the response to thyrotropin in human thyroid membranes. Endocrinol 123:1535,1988.
70. Davies TF, Platzer M. hCG-induced TSH receptor activation and growth acceleration in FRTL-5 thyroid cells. Endocrinol 118:2149,1986.
71. Hershman JM, Lee H-Y, Sugawara M, Mirell CJ, Pang X-P, Yanigasawa M, Pehany AE. Human chorionic gonadotropin stimulates iodide uptake, adenylate cyclase, and deoxyribonucleic acid synthesis in cultured rat thyroid cells. J Clin Endocrinol Metab 67:74,1988.
72. Hershman JM, Higgins P. Hydatidiform mole - a cause of clinical hyperthyroidism. N Engl J Med 284: 573,1971.
72a. Misra M, Levitsky LL, Lee MM. Transient hyperthyroidism in an adolescent with hydatidiform mole. J Pediatr. 140:362-6, 2002.
73. Dowling JT, Ingbar SH, Frenkel N. Iodine metabolism in hydatidiform mole and choriocarcinoma. J Clin Endocrinol Metab 20:1,1960.
74. Kock H, Kessel HV, Stolte L, vLeusden H. Thyroid function in molar pregnancy. J Clin Endocr Metab 26:1128,1966.
75. Galton VA. Abnormalities of thyroid hormone economy in patients with hydatidiform mole. Progr. Annual meeting of the ATA. Washington DC. Oct. 10-12,1968. p 35.
76. Mann LI, Lutz M, Schulman H, Romney SL. Hydatidiform mole with hyperthyroidism. Am J Obstet Gynec 98:1151,1967.
77. Higgins HP, Hershman JM, Kenimer JG, Patillo RA, Bayley TA and Walfish P. The thyrotoxicosis of hydatiform mole. Ann Int Med 83:307,1975.
78. Yoshimura M, Pekary AE, Pang X-P, Berg L, Goodwin TM, Hershman JM. Thyrotrophic activity of basic isoelectric forms of human chorionic gonadotropin in extracted from hydatiform mole tissues. J Clin Endocrinol Metab 78:862,1994.
79. Anderson NR, Lokich JJ, McDermott WV jr, Trey C, Falchuk KR. Gestational choriocarcinoma and thyrotoxicosis. Cancer 44:304,1979.
79a. Hosoi Y. Murakami M, Minegishi T, Okano H, Ibuki Y, Takeuchi T, Mori M. Stimulation of Chinese hamster ovary cells expressing human thyrotropin receptors by serum human chorionic gonadotropin of patients with hydatidiform mole. Thyroid 9:1205-1210,1999.
80. Orgiazzi JJ, Rousset B, Cosentino C, Tournière J, Dutrieux N. Plasma thyrotropic activity in a man with choriocarcinoma. J Clin Endocrinol Metab 39:653,1974.
80a. Yoshimura M, Hershman JM. Thyrotropic action of human chorionic gonadotropin. Thyroid 5:425-434,1995
81. Orgiazzi JJ, Mornex R. Hyperthyroidism. In: The thyroid gland. Ed. MA Greer, Raven Press New York. 1990, p 442.
82. Hennemann G. Historical aspects about the development of our knowledge of morbus Basedow. J Endocrinol Invest 14:617,1991.
83. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine 62:1,1983.
84. Connolly RJ, Vidor GI, Stewart JC. Increase in thyrotoxicosis in endemic goiter area after iodination of bread. Lancet 1:500,1970.
85. Stewart JC, Vidor GI. Thyrotoxicosis iduced by iodine contamination of food - a common unrecognized condition? Br Med J 1:372,1976.
85a. Stanbury JB, Ermans AE, Pourdiux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8:83-100,1998
86. Leger AF, Laurent M-F, Savoie J-C. Surcharge iodée pathologie thyreoïdienne iatrogène. Ann Endocrinol 42:446,1981.
87. Herrmann J, Krüskemper HL. Gefardung von Patienten mit latenter und manifester Hyperthyreose durch jodhaltige Röntgenkontrastmittel und Medikamente. Deutsche Medizin Wochenschr 103:1437,1978.
87a. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J. Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. Eur J Endocrinology 140:264-267,1999
88. Leger AF et al. Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases. Eur J Clin Invest 14:449,1984.
89. Martin FIR, Tress BW, Colman P, Deam DR. Iodine-induced hyperthyroidism due to nonionic contrast radiography in the eldery. Am J Med 95:78, 1993.
90. Mariotti S, Pinchera A. Role of the immune system in the control of thyroid function. In: The thyroid gland. Ed. Greer MA, Raven Press Ltd New York 1990:147.
91. Many M-C, Mestdagh C, van den Hove M-F, Denef JF. In vitro study of acute toxic effects of high iodide dosis in human thyroid follicles. Endocrinology 131:621,1992.
92. Mazson PD, Williams ML, Cantley LK, Dalldorf FG, Utiger RD, Foster JR. Myxedema coma during long-term amiodarone therapy. Am J Med 77:751,1984
92a. Martino E, Aghini-Lombardi F, Bartalena L, et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Int Med 154:12-26,1994
92aa. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 100:149-154,1999.
92ab. van Beeren HC, Bakker O, Wiersinga WM. Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. FEBS Lett 481:213-6, 2000
92ac. BogazziF, Bartalena L, Gasperi M, Braverman LE, Martono E. The various effects of amiodarone on thyroid function. Thyroid 11:511-519,2001.
92ad. Bogazzi F, Martino E, Dell'Unto E, Brogioni S, Cosci C, Aghini-Lombardi F, Ceccarelli C, Pinchera A, Bartalena L, Braverman LE.Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2003 Jul;26(7):635-40.
92ae. (Chopra IJ and Baber K. Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. J Clin Endocrinol Metab 86:4707-4710, 2001).
92b.Cappiello E, Boldorini R, Tosoni A, et al. Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. J Endorinol Invest 18:862-868,1995
93. Bogazzi F, Bartalena L, Brogioni S, et al. Color flow doppler sonography differentiates type 1 and type 2 amiodarone-induced thyrotoxicosis. Thyroid 7:541-545,1997
94.Bartalena L, Brogioni S,Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge:results of a prospective study. J Endocrinol Metab 81:2930-2933,1996
95. Martino E, Aghini-Lombardi F, Mariotti S, Lenziardi M, Basschieri L, Braverman LE, Pinchera A. Treatment of amiodarone-associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 5:201,1986.
96. Reichert LJ, de Rooy HA. Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. Br Med J 298:1547,1989.
97. Roti E et al. Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 75:1273,1992.
98. Martino E, Aghini-Lombardi F, Mariotti S et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 26:158,1987.
100. Emerson CH, Utiger RD. Hyperthyroidism and excessive thyrotropin secretion. N Engl J Med 287:328,1972.
101. Gershengorn MC, Weintraub BD. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistence to thyroid hormone. J Clin Invest 56:633,1975.
102. Rösler A, Litvin Y, Hage C, Gross J, Cerasi E. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab 54:76,1982.
103. Tolis G, Bird C, Bertrand G, McKenzie JM, Azrin C. Pituitary hyperthyroidism. Am J Med 64:177,1978.
104. Smallridge RC, Smith CE. Hyperthyroidism due to thyrotropin-secreting pituitary tumors. Diagnostic and therapeutic considerations. Arch Int Med 143:503,1983.
104a. McDermott MT, Ridgway EC. Central hyperthyroidism. Endocrinol Metab Clin North Am 27:187-203,1998
104b. Sergi E, Medri G, Papandreou Mj, et al. Polymorphism of thyrotropin and alpha subunit in human pituitary adenomas. J Endocrinol Invest 16:45-55,1993
106. Gesundheit N, Petrick PA, Nissim M, Dahlberg PA, Doppman JL, Emerson CH, Braverman LE, Oldfield EH, Weintraub BD. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of 9 patients. Ann Intern Med 111:827,1989.
107. Yovos JG, Falko JM, O-Dorisio TM, Marlakey WB, Cataland S, Capen CC. Thyrotoxicosis and a thyrotropin-secreting pituitary tumor causing unilateral exophthalmos. J Clin Endocrinol Metab 53:338,1981.
108. Hill SA, Falko JM, Wilson CB, Hunt WE. Thyrotrophin-producing pituitary adenomas. J Neur Surg 57:515,1982.
108a. Sanno N, teramoto A, Osamura RY. Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol 54:179-86,2001.
109. Benoit R et al. Hyperthyroidism due to a pituitary TSH secreting tumour with amenorrhoea-galactorrhoea. Clin Endocrinol 12:11,1980.
110. Lamberg BA et al. Hyperthyroidism and acromegaly caused by a pituitary TSH- and GH-secreting tumour. Acta Endocrinol (Copenh) 103:7,1983.
111. Shimatsu A, Murabe H, Kamoi K, Susuki Y, Nakao K. Treatment of thyrotropin-secreting pituitary adenomas with octreotide. Endocr J 46:113-123,1999
112. Polak M et al. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment. Acta Endocrinol (Copenh) 1224:479,1991.
113. Chanson Ph, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone secreting pituitary adenomas. Ann Int Med 119:236,1993.
113a Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth M, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85:1487-1491, 2000.
113b. (Pichler R, Maschek W. Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline. Europ J Endocrinol 144:179-180, 2001)
114. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet. 7:396,1994
114a. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H et al. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin receptor gene. New Eng J Med 332:150,1995.
114b.Guters A, Schonberg T, Biebermann H, et al. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J Clin Endocrinol Metab 83:1431-1436,1998
114c. Tonacchera M, Agretti P, Rosellini V, Ceccarini G, Perri A, Zampolli M, Longhi R, Larizza D, Pinchera A, Vitti P, Chiovato L. Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene Thyroid 10:859-863,2000
114d. Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and Glutamic Acid 157 of the TSH Receptor: Two Interacting Residues with a Key Role in Determining Specificity toward TSH and Human CG. Mol Endocrinol. 16:722-35,2002
115. Ehrenheim C, Heintz P, Schober O, Schicha H, Hundeshagen H. Jodinduzierte T3-Hyperthyreose beim metastasierenden follikularen Schilddrüsen Karzinom. Nuklear Medizin 25:201,1986.
115a. Salvatori M, Saletnich I, Rufini V, et al. Severe thyrotoxicosis due to functioning pulmonary metastasis of well -differentiated cancer. J Nucl Med 39:1202-1207,1998
116. Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. Endocrinol Metab Clin North Amer. 19:593,1990.
117. Nakashima T, Enue K, Shiro-osu A, Yoshinari M, Okamura K, Itoh M. Predominant T3 synthesis in the metastatic thyroid carcinoma in a patient with T3-toxicosis. Metabolism 30:327,1981.
118. Verschueren CP, Rutteman GR, Vos JH, Van Dijk JE, De Bruin TWA. Thyrotrophin receptors in normal and neoplastic (primary and metastatic) canine thyroid tissue. J Endocrinol 132: 461, 1992.
119. Rosario F, Marques AR, Roque L, Rodrigues R, Ferreira TC, Limbert E, Sobrinho L, Leite V Metastatic follicular carcinoma associated with hyperthyroidism.Clin Nucl Med. 2005 Feb;30(2):79-82
120. Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA 242:269,1979.
121. Grayzel EF, Bennett B. Graves' disease, follicular thyroid carcinoma and functioning pulmonary metastases. Cancer 43:1885,1979.
122. Kasagi K, Takeichi R, Miyamoto S, Misaki T, Inoue D et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol 40:429,1994.
123. Steffensen FH, Aunsholt N Aa. Hyperthyroidism associated with metastatic thyroid carcinoma. Clin Endocrinol 41:685,1994.
124. Mazzaferri EL. Editorial. Thyroid cancer and Graves' disease. J Clin Endocrinol Metab 70:826,1990.
125. Belfiore A, Charofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R. Increased agressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 70:830,1990.
126. Hales IB et al. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab 75:886,1992.
127. Tamsen A, Mazur MT. Ovarian strumal carcinoid in association with multiple endocrine neoplasia, type IIA. Arch Pathol Lab Med 116:200,1992.
128. Sakura H, Fujii T, Okamoto K. A study of human calcitonin in an ovarian carcinoid and ovarian cancers. Exp Clin Endocrinol 97:91,1991.
129. Ozerwenka KF, Schon HJ. Bock P. Immunochemical and ultrastructural studies of an ovarian strumal carcinoid. Wien Klin Wochenschr 102:687,1990.
130. Kempers RD, Dockerty MB, Hoffman DL et al. Struma ovarii-ascitic, hyperthyroid and asymptomatic syndromes. Ann Int Med 72:883,1970.
131. Pardo-Mindan FJ, Vazquez JJ. Malignant struma ovarii. Light and electron microscopic study. Cancer 51:337,1983.
131a. Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am 27:169-158,1998
131b. Simkin PH, Ramirez LA, Zweizig SL, Alfonso SA,Fraire AE, et al. Monomorphic teratoma of the ovary: a rare cause of triiodothyronine toxicosis. Thyroid 9:949-954,1999.
132a. Zalel Y, Seidman DS, Oren M, Achiron R, Gotlieb W, Mashiach S, Goldenberg M Sonographic and clinical characteristics of struma ovarii. Ultrasound Med 19:857-61,2000.
132b. Ciccarelli A, Valdes-Socin H, Parma J, Khoo SK, Schoumans J, Colao A, Hamoir E, Beckers A.Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies.Eur J Endocrinol. 2004 Apr;150(4):431-7.